DR10624 clinical trials
How each study uses DR10624 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the DR10624 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- DR10624 Injection
- 4
Studies by the year they started
7 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Zhejiang Doer Biologics Co., Ltd. (6) · Junbo Ge (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test DR10624.
- Dec 2026A Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic PlaqueNot applicable · Junbo Ge
Studies
Open first, then newest update. How each study uses DR10624 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney DiseaseNot yet recruitingPhase 2Zhejiang Doer Biologics Co., Ltd.NCT07848880Written as DR10624 Injection
- A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe HypertriglyceridemiaNot yet recruitingPhase 3Zhejiang Doer Biologics Co., Ltd.NCT07693777Written as DR10624 Injection
- A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe HypertriglyceridemiaNot yet recruitingPhase 3Zhejiang Doer Biologics Co., Ltd.NCT07680829Written as DR10624 Subcutaneous Injection
- A Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic PlaqueEnrolling by invitationNot applicableJunbo GeNCT07050134Written as DR10624 Injection;
- A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624CompletedPhase 1Zhejiang Doer Biologics Co., Ltd.NCT05378893Written as DR10624 for injection
- Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD SubjectsActive, not recruitingPhase 2Zhejiang Doer Biologics Co., Ltd.NCT07024212Written as DR10624 Injection
- A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe HypertriglyceridemiaCompletedPhase 2Zhejiang Doer Biologics Co., Ltd.NCT06555640Written as DR10624 Injection